WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H413591
CAS#: 66211-92-5 (free base)
Description: Detorubicin Free Base is a semi-synthetic derivative of the anthracycline antineoplastic antibiotic daunorubicin. Detorubicin intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. Detorubicin is less toxic than daunorubicin.
Hodoodo Cat#: H413591
Name: Detorubicin Free Base
CAS#: 66211-92-5 (free base)
Chemical Formula: C33H39NO14
Exact Mass: 673.24
Molecular Weight: 673.670
Elemental Analysis: C, 58.84; H, 5.84; N, 2.08; O, 33.25
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Related CAS #: 64291-45-8 (HCl) 66211-92-5 (free base)
Synonym: Detorubicin Free Base; RP33921; RP-33921; RP 33921
IUPAC/Chemical Name: 2-((2S,4S)-4-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)-2-oxoethyl 2,2-diethoxyacetate
InChi Key: XZSRRNFBEIOBDA-CFNBKWCHSA-N
InChi Code: InChI=1S/C33H39NO14/c1-5-44-32(45-6-2)31(41)46-13-20(35)33(42)11-16-23(19(12-33)48-21-10-17(34)26(36)14(3)47-21)30(40)25-24(28(16)38)27(37)15-8-7-9-18(43-4)22(15)29(25)39/h7-9,14,17,19,21,26,32,36,38,40,42H,5-6,10-13,34H2,1-4H3/t14-,17-,19-,21-,26+,33-/m0/s1
SMILES Code: CCOC(C(OCC([C@]1(C[C@@H](c2c(C1)c(O)c3c(C(c4c(C3=O)cccc4OC)=O)c2O)O[C@H]5C[C@@H]([C@@H]([C@@H](O5)C)O)N)O)=O)=O)OCC
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: To be determined
Shelf Life: >2 years if stored properly
Drug Formulation: To be determined
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 673.67 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Chawla SP, Legha SS, Benjamin RS. Detorubicin--an active anthracycline in untreated metastatic melanoma. J Clin Oncol. 1985 Nov;3(11):1529-34. doi: 10.1200/JCO.1985.3.11.1529. PMID: 4056844.
2: Deprez-de Campeneere D, Baurain R, Trouet A. Pharmacokinetic, toxicologic, and chemotherapeutic properties of detorubicin in mice: a comparative study with daunorubicin and adriamycin. Cancer Treat Rep. 1979 May;63(5):861-7. PMID: 455327.
3: Dantchev D, Slioussartchouk V, Paintrand M, Hayat M, Bourut C, Mathé G. Electron microscopic studies of the heart and light microscopic studies of the skin after treatment of golden hamsters with adriamycin, detorubicin, AD-32, and aclacinomycin. Cancer Treat Rep. 1979 May;63(5):875-88. PMID: 455329.
4: Chauvergne J, Bui NB, Cappelaere P, Gary-Bobo J, Guerrin J, Armand JP, Durand M. Chimiothérapie des mélanomes malins évolués. Résultats d'un essai contrôlé comparant l'association de détorubicine et de dacarbazine (DTIC) à la dacarbazine seule [Chemotherapy in advanced malignant melanoma. Results of a controlled trial comparing a combination of dacarbazine (DTIC) and detorubicin with dacarbazine alone]. Sem Hop. 1982 Dec 16;58(46):2697-701. French. PMID: 6297068.
5: Sørensen JB. Current concepts in chemotherapy for malignant pleural mesothelioma. Clin Respir J. 2008 Apr;2(2):74-9. doi: 10.1111/j.1752-699X.2008.00046.x. PMID: 20298310.
6: Jacquillat C, Auclerc MF, Weil M, Maral J, Degos L, Auclerc G, Tobelem G, Schaison G, Bernard J. Clinical activity of detorubicin: a new anthracycline derivative. Cancer Treat Rep. 1979 May;63(5):889-93. PMID: 455330.
7: Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol. 1996 Mar;14(3):1007-17. doi: 10.1200/JCO.1996.14.3.1007. PMID: 8622005.
8: Preliminary results of a phase II trial on solid tumors of detorubicin, a new anthracyclin. Cancer Clin Trials. 1980 Summer;3(2):115-20. PMID: 7428135.
9: Zenebergh A, Baurain R, Trouet A. Cellular pharmacology of detorubicin and doxorubicin in L1210 cells. Eur J Cancer Clin Oncol. 1984 Jan;20(1):115-21. doi: 10.1016/0277-5379(84)90042-7. PMID: 6537910.
10: Clinical study of detorubicin. EORTC Clinical Screening Group. Recent Results Cancer Res. 1980;74:184-91. PMID: 7444139.
